NCT04397770 2020-05-21
Camrelizumab Plus Apatinib and Temozolomide as First Line Therapy in Advanced Acral Melanoma
Peking University Cancer Hospital & Institute
Phase 2 Unknown
Clinical Trials
3 trialsNCT03955354 2019-05-20
PD-1 Antibody SHR-1210 Combined With Apatinib of First-line Treatment of Advanced Acral Melanoma
Peking University Cancer Hospital & Institute
Phase 2 Unknown
NCT03383237 2017-12-27
Clinical Study of Apatinib as the Second-line Therapy in Malignant Melanoma
Henan Cancer Hospital
Phase 2 Unknown